AT1 FY21 - General Discussion + FA, page-280

Hi Freeman1, sorry, I mis-read your post as asking for the "$5m" revenue sources (which was the FY20 annual rev, hence pointed you to the FY20 Resultrs presso+thread, which of course won't have any Q1 FY21 detail in it...oops. sorry for wasting your time).

No, we don't know the Q1 revenue breakdown. The company is not obliged to release this detail in qtrlies, so we may see more growth/comparison detail in Q2 results (as that leads into half-yearly report anyway) or have to wait for half-yearly doc to get the breakdown.

We assume most of this is from ongoing Mylan's HIV expansion + Covid-19 test sales to NGBio (EU)....we think some of it also maybe from pending FY20 receivables for Covid19 + HIV/hCG test etc...but we cannot confirm this. Need more financial + annual capital workflow patterns, which will only become clearer after few more qtrlies.